The EPS projection of NeoGenomics, Inc. (NASDAQ:NEO) for quarter ended 2016-09-30 is $0.02. Last week, the projection for EPS was $0.02 against target of $0.02, a month earlier. While 2-months ago, this projection was $0.02 versus forecast of $0.02a quarter months earlier, posting a deviation of 0%.
NeoGenomics, Inc. (NASDAQ:NEO) posted that 18 days earlier, the share price was revised 1 times on upside. In addition, negative revisions were 0.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 3, and 3, correspondingly.
The per-share earnings downgrade for NeoGenomics, Inc. (NASDAQ:NEO) in the preceding 30 and 120 were 0 and 0. While in 60 and 90 days were 0, and 0, in that order.
NeoGenomics, Inc. (NASDAQ:NEO) EPS target was $0.02 for the quarter closed 1. It was based on 3 calls. As on 2016-04-27 the EPS was $0.04. The change was $0.14, posting a deviation of 140%. The price projections gave a standard deviation of 0.03.
Quarterly Sales Estimates
NeoGenomics, Inc. (NASDAQ:NEO) sales prediction for the fiscal 2016 stands at $64.943 and the median estimate is at $64.935. Almost 4 analysts gave sales target.
Among this, the highest sales estimate is $66.1 while the lowest target is $63.802 showing standard deviation of 1.041%.
As many as 4 analysts have positive sales targets revision while 4 reduced sales estimates, posting a deviation of 0%.
Last month, 4 experts have positive sales number revision. Also, 4 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 4 hiked sales target and 4 reduced sales forecast, posting a deviation of -1.351%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...